Famotidine vs prilosec
Pro Research Analysisby 
Searched over 200M research papers
Famotidine vs. Prilosec: A Comparative Analysis
Treatment Efficacy in Peptic Ulcer
Famotidine and Prilosec Effectiveness
In a study comparing the effectiveness of famotidine and omeprazole (Prilosec) in treating peptic ulcers, 37 patients were divided into two groups: one treated with famotidine and the other with omeprazole. The results showed that the total effective rate was 90% for the famotidine group and 70.6% for the omeprazole group. However, patients treated with omeprazole exhibited better clinical signs of improvement and faster wound healing times compared to those treated with famotidine1. This suggests that while famotidine may have a higher overall effectiveness rate, omeprazole may offer quicker symptomatic relief and healing.
Impact on Antiplatelet Therapy in Acute Coronary Syndromes
Platelet Reactivity and Cardiovascular Events
A prospective, randomized study investigated the influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in patients with acute coronary syndromes (ACS) who were also taking aspirin. The study included 130 patients who underwent stent implantation and were assigned to receive either omeprazole or famotidine. The findings indicated no significant difference in the platelet reactivity index (PRI) between the two groups (55±17% for omeprazole vs. 51±19% for famotidine; P=0.26). Additionally, the cumulative rate of adverse cardiovascular events at 12 months was similar between the groups (13% for omeprazole vs. 17% for famotidine; P=0.81)2. This suggests that both medications have a comparable impact on platelet function and cardiovascular outcomes in ACS patients.
Specific Findings in STEMI and Non-STEMI Patients
Further analysis revealed that among patients with ST-elevation myocardial infarction (STEMI), the PRI was similar between the omeprazole and famotidine groups (54.9±17.9% vs. 54.0±17.8%; P=0.83). However, there was a trend toward a higher PRI in the omeprazole group compared to the famotidine group among patients without persistent ST-segment elevation ACS (55.2±15.9% vs. 46.4±19.4%; P=0.06)2. This indicates that while omeprazole and famotidine are generally comparable, there may be slight differences in their effects on platelet reactivity in specific subgroups of ACS patients.
Conclusion
In summary, both famotidine and omeprazole are effective treatments for peptic ulcers, with famotidine showing a higher overall effectiveness rate but omeprazole providing faster symptomatic relief and wound healing. In the context of ACS, both medications have a similar impact on platelet reactivity and cardiovascular outcomes, although slight differences may exist in specific patient subgroups. These findings can guide clinicians in choosing the appropriate medication based on the specific needs and conditions of their patients.
Sources and full results
Most relevant research papers on this topic
The old 37 cases treatment of peptic ulcer
Using prilosec for chronic peptic ulcer treatment in older patients has a more obvious clinical effect and faster wound healing time compared to famotidine.
Observational StudyInfluence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Concomitant use of low-dose omeprazole does not significantly attenuate the antiplatelet effects of clopidogrel in patients with acute coronary syndromes, especially in those with STEMI.
RCTFamotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
High-dose famotidine significantly reduces the cumulative incidence of both gastric and duodenal ulcers in patients with arthritis receiving long-term NSAID therapy.
RCT
Highly CitedFamotidine
Famotidine may be an effective and well-tolerated alternative to cimetidine and ranitidine for healing peptic ulcers, but more clinical experience is needed for long-term maintenance treatment and Zollinger-Ellison syndrome patients.
RCTFamotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial
Famotidine effectively prevents peptic ulcers and erosive oesophagitis in patients taking low-dose aspirin for vascular protection, with fewer adverse events than placebo.
RCT
Large Human Trial
Rigorous JournalHighly CitedOral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Famotidine is a safe and well-tolerated treatment for mild to moderate COVID-19, leading to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity.
RCTRigorous JournalFamotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
High-dose famotidine is inferior to pantoprazole in preventing recurrent dyspeptic or bleeding ulcers/erosions in patients with aspirin-related peptic ulcers/erosions.
RCTHighly CitedComparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Famotidine does not show a reduced risk of COVID-19 outcomes in hospitalized patients compared to those who do not use it or those who use PPI or hydroxychloroquine.
Observational StudyDouble-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
Famotidine subjectively improves children's abdominal pain symptoms but is less effective objectively, but is significantly more effective for children with peptic symptoms.
RCTFamotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study
Famotidine 20 mg BID effectively relieves daytime heartburn and heals esophageal erosions and ulcerations, with a greater proportion of patients experiencing complete endoscopic healing than placebo.
RCTLarge Human TrialHighly Cited